The FDA said the policy would shift to an individual assessment that evaluates an individual’s risk regardless of gender or sexual orientation.
The FDA said the policy would shift to an individual assessment that evaluates an individual’s risk regardless of gender or sexual orientation.
){kind=link}
Comments
Comments are disabled for this post.